Last updated on March 2019

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular Marginal Zone or Mantle Cell Lymphoma.


Brief description of study

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is an immunomodulatory agent with direct and immune-mediated mechanisms of action, as well as clinical activity in NHL. Recent studies in frontline and relapsed/refractory NHL show high activity for lenalidomide plus rituximab (R2), supporting further study of this combination.

Detailed Study Description

MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received 1 prior therapy and had stage I-IV, measurable disease. ~500 patients are planned for enrollment in 12 cycles of R2 induction, with a projected ~314 patients with SD after induction randomized (1:1) to two maintenance arms. Induction includes oral lenalidomide 20 mg/day, days 1-21 per 28-day cycle (d1-21/28) plus IV rituximab 375 mg/m2, days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 3, 5, 7, 9, and 11 (28-day cycles). Patients are then randomized to maintenance lenalidomide 10 mg/day, d1-21/28, cycles 13-30, plus rituximab 375 mg/m2, day 1 of cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 (R2, Arm A), or rituximab alone (same schedule, Arm B). Patients receiving R2 maintenance after 18 cycles may continue maintenance lenalidomide monotherapy 10 mg/day, d1-21/28 (per patient and/or investigator discretion), until disease progression as tolerated. The primary endpoint is progression-free survival (per modified 1999 IWG criteria). Secondary endpoints include safety, overall survival, response rates, duration of response, and quality of life (exploratory). Patients will be followed for 5 years after the last patient initiated induction therapy. Enrollment in MAGNIFY began in March 2014; as of Jan 2016, 133 patients are enrolled.

Clinical Study Identifier: NCT01996865

Find a site near you

Start Over

Arizona Oncology

Tucson, AZ United States
  Connect »

Sutter East Bay Hospitals

Berkeley, CA United States
  Connect »

John Muir Health

Concord, CA United States
  Connect »

Sutter Hematology and Oncology

Sacramento, CA United States
  Connect »

Sharp Memorial Hospital

San Diego, CA United States
  Connect »

Sansum Clinic

Santa Barbara, CA United States
  Connect »

VA Eastern Colorado

Denver, CO United States
  Connect »

VVH Cancer Center Valley View Hospital

Glenwood Springs, CO United States
  Connect »

Whittingham Cancer Center

Norwalk, CT United States
  Connect »

Hematology and Oncology

Waterbury, CT United States
  Connect »

Florida Cancer Affiliates

New Port Richey, FL United States
  Connect »

Alexian Brothers Hospital Network

Elk Grove Village, IL United States
  Connect »

Oncology Specialists, PC

Park Ridge, IL United States
  Connect »

Baptist Healthcare System, Inc.

Louisville, KY United States
  Connect »

Maine General Medical Center

Waterville, ME United States
  Connect »

Anne Arundel Medical Center

Annapolis, MD United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Central Care Cancer Center

Bolivar, MO United States
  Connect »

Mercy Medical Research Institute

Springfield, MO United States
  Connect »

Saint Peter's University Hospital

New Brunswick, NJ United States
  Connect »

Broome Oncology, LLC

Johnson City, NY United States
  Connect »

Clinical Research Alliance

Lake Success, NY United States
  Connect »

Rex Cancer Center

Raleigh, NC United States
  Connect »

Aultman Hospital

Canton, OH United States
  Connect »

Oncology Hematology Care, Inc.

Cincinnati, OH United States
  Connect »

MetroHealth Medical Systems

Cleveland, OH United States
  Connect »

Rapid City Regional Hospital

Rapid City, SD United States
  Connect »

Avera Cancer Institute

Sioux Falls, SD United States
  Connect »

Baptist Cancer Center

Memphis, TN United States
  Connect »

Arlington Cancer Center

Arlington, TX United States
  Connect »

Texas Oncology-Arlington South

Arlington, TX United States
  Connect »

Texas Oncology

Dallas, TX United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Millenium Oncology

Houston, TX United States
  Connect »

Utah Cancer Specialist

Salt Lake City, UT United States
  Connect »

Fort Belvoir Community Hospital

Fort Belvoir, VA United States
  Connect »

Vista Oncology, Inc.

Olympia, WA United States
  Connect »

DN Greenwald Center

Mukwonago, WI United States
  Connect »

Oconomowoc Memorial Hospital

Oconomowoc, WI United States
  Connect »

Waukesha Memorial Hospital

Waukesha, WI United States
  Connect »

CentralCare Cancer Center

Great Bend, KS United States
  Connect »

Kliniken Maria Hilf GmbH

Mönchengladbach, Germany
  Connect »